This is the competing renewal for CA548o7 Objectives during the past cycle of this project included the determination of a) autocrine TGF alpha function and b) mechanisms controlling TGF alpha expression in colon cancers. Accomplishments have included the determination that autocrine TGF alpha: in both early and late stage colon cancers functions primarily in the process of re-entering the cycling state from environmental conditions which limit cell growth (e.g.. growth factor deprivation) and does not appear to have a significant role in actively cycling populations (e.g., exponential growth in tissue culture). Late stage colon cancer cell lines differ from early stage cells in that they are completely independent of exogenous growth factors for re-initiation of DNA synthesis from growth arrest whereas early stage cells require an exogenous insulin-like growth factor l receptor (IGFIR) ligand for cell cycle re-entry. We have found that the growth factor independence of late stage malignant cells arises from inappropriate TGF alpha: expression (not overexpression) and EGF receptor (EGFR) activation in growth arrested cells. This has the effect of producing constitutive EGFR activation, an event long associated with transformation. Early stage cells do not express TGF ALPHA: or show significant EGFR activation at growth arrest. IGFIR activation in early stage cells regenerates their autocrine TGF ALPHA: expression and EGFR activation events which we have shown to be necessary for DNA synthesis in these cells. Finally, we have found that autocrine TGF~ represses autocrine TGF~ expression in early stage cells. Inhibition of TGF~ function leads to enhanced expression of autocrine TGF ALPHA: and EGFR activation in growth arrested cells along with the acquisition of independence from exogenous growth factors and malignant progression to a late stage phenotype. Exogenous TGFj3 treatment also blocks IGFIR mediated induction of TGF ALPHA: mRNA in early stage cells. Several issues arise from these results. The first issue we will address is the mechanism by which IGFIR activation stimulates TGF ALPHA: re- expression from the growth arrested state. The second issue that will be addressed in the renewal project is the mechanism by which TGFj3 suppresses TGF alpha expression. The results from the last cycle of the project have shown that inappropriate expression of TGF alpha provides growth factor independence, but they have not addressed how inappropriate TGF alpha expression carries this out. Therefore, this issue will also be addressed in the renewal project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA054807-13
Application #
6626642
Study Section
Special Emphasis Panel (ZRG1-ET-2 (03))
Program Officer
Perry, Mary Ellen
Project Start
1991-08-01
Project End
2004-12-31
Budget Start
2003-01-01
Budget End
2003-12-31
Support Year
13
Fiscal Year
2003
Total Cost
$269,076
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Leiphrakpam, Premila D; Brattain, Michael G; Black, Jennifer D et al. (2018) TGF? and IGF1R signaling activates protein kinase A through differential regulation of ezrin phosphorylation in colon cancer cells. J Biol Chem 293:8242-8254
Contreras, Jacob I; Robb, Caroline M; King, Hannah M et al. (2018) Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy. ACS Chem Biol 13:1148-1152
Robb, Caroline M; Kour, Smit; Contreras, Jacob I et al. (2018) Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget 9:5216-5232
Bailey, Katie L; Agarwal, Ekta; Chowdhury, Sanjib et al. (2017) TGF?/Smad3 regulates proliferation and apoptosis through IRS-1 inhibition in colon cancer cells. PLoS One 12:e0176096
Robb, Caroline M; Contreras, Jacob I; Kour, Smit et al. (2017) Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem Commun (Camb) 53:7577-7580
Agarwal, E; Robb, C M; Smith, L M et al. (2017) Role of Akt2 in regulation of metastasis suppressor 1 expression and colorectal cancer metastasis. Oncogene 36:3104-3118
Fisher, Kurt W; Das, Binita; Kim, Hyun Seok et al. (2015) AMPK Promotes Aberrant PGC1? Expression To Support Human Colon Tumor Cell Survival. Mol Cell Biol 35:3866-79
Leiphrakpam, Premila D; Agarwal, Ekta; Mathiesen, Michelle et al. (2014) In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer. Oncol Rep 31:87-94
Leiphrakpam, Premila D; Rajput, Ashwani; Mathiesen, Michelle et al. (2014) Ezrin expression and cell survival regulation in colorectal cancer. Cell Signal 26:868-79
Agarwal, Ekta; Chaudhuri, Anathbandhu; Leiphrakpam, Premila D et al. (2014) Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer. BMC Cancer 14:145

Showing the most recent 10 out of 49 publications